Trial Profile
A retrospective study to evaluate the role of HLA-Cw*0602 as a pharmacogenetic marker of response to ustekinumab in patients with Psoriasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2017
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriasis
- Focus Pharmacogenomic; Therapeutic Use
- 09 Jun 2017 New trial record